Aktis Oncology, Inc.

NASDAQ:AKTS

Biotechnology

Healthcare
$16.10 +0.47%

+$0.11 today

Market cap
$865.32M
Beta
1.10
P/E (TTM)
-28.7
EPS (TTM)
-$0.82
52W Low $14.72High $29.16

Volume 0.44M

Average 0.33M

AKTS Deferred Tax Liabilities

Taxes owed in future periods because of timing differences between accounting and tax rules.

Aktis Oncology, Inc.NASDAQ: AKTS

Deferred Tax Liabilities · Q1 FY2026 · quarter ended Mar 2026

Deferred tax liabilities of $0 in Q1 FY2026

Q1 FY2026 deferred tax liabilities was $0.

Context

  • Deferred tax liabilities amounted to 0.0% of total assets at the end of Q1 FY2026.
  • Deferred tax liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Deferred Tax Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Tax Liabilities history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Tax Liabilities vs competitors

How AKTS compares with its peers on the latest reported figures

  • AKTS's Mar 2026 deferred tax liabilities of $0 is the highest of the 6 companies compared; the peer median is $0.
  • Deferred tax liabilities amounts to 0.0% of total assets for AKTS, versus a peer median of 0.0%.
AKTS Competitors Peer median
Deferred Tax Liabilities for AKTS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AKTSAktis Oncology, Inc.Mar 2026$0 ——0.0%
IMNMImmunome, Inc.Sep 2026$0 ——0.0%
IMCRImmunocore Holdings plcMar 2026$0 ——0.0%
AURAAura Biosciences, Inc.Mar 2026$0 ——0.0%
BCYCBicycle Therapeutics plcMar 2026$0 ——0.0%
MGNXMacroGenics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding AKTS) $0——0.0%

Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents128.6M29.51M37.16M37.78M
Short-term Investments068.35M260.01M189M
Net Receivables0000
Inventory0000
Other Current Assets3.88M2.34M3.69M3.52M
Total Current Assets132.48M100.2M300.85M230.31M
Property, Plant & Equipment (Net)4.87M20.92M20.87M27.25M
Goodwill0000
Intangible Assets0000
Long-term Investments0000
Tax Assets0000
Other Non-current Assets976K1.23M4.46M7.33M
Total Non-current Assets5.84M22.15M25.33M34.58M
Total Assets138.32M122.36M326.18M264.89M
Account Payables490K957K1.92M1.74M
Short-term Debt0000
Tax Payables0000
Deferred Revenue009.28M18.66M
Other Current Liabilities1.19M2.03M3.08M4.56M
Total Current Liabilities5.28M6.24M18.82M31.24M
Long-term Debt0000
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0051.04M36.16M
Other Non-current Liabilities151.36M150.55M333.41M333.41M
Total Non-current Liabilities152.28M162.42M395.16M379.8M
Total Liabilities157.55M168.66M413.98M411.03M
Common Stock0000
Retained Earnings(20.21M)(48.85M)(92.83M)(156.56M)
Accumulated OCI082K124K42K
Other Stockholders Equity0000
Minority Interest0000
Total Equity(19.23M)(46.31M)(87.8M)(146.15M)
Total Debt1.78M13.4M12.01M11.55M
Net Debt(126.82M)(16.11M)(25.15M)(26.24M)

Aktis Oncology, Inc.

NASDAQ:AKTS

Intrinsic Alpha fair value

Locked

Current Price

$16.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.